[{"id":"306f2837-4ae2-43cc-8471-5706f09281e5","acronym":"ELAINE 3","url":"https://clinicaltrials.gov/study/NCT05696626","created_at":"2023-01-25T16:59:42.976Z","updated_at":"2025-02-25T12:38:31.246Z","phase":"Phase 3","brief_title":"Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation","source_id_and_acronym":"NCT05696626 - ELAINE 3","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" ER","pipe":" | ","alterations":" ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-24"},{"id":"3d373e1f-fe2b-41f0-84e9-9ccc47be3cca","acronym":"Pangeia-2","url":"https://clinicaltrials.gov/study/NCT06417801","created_at":"2024-05-18T04:15:22.395Z","updated_at":"2025-02-25T15:14:39.218Z","phase":"","brief_title":"Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.","source_id_and_acronym":"NCT06417801 - Pangeia-2","lead_sponsor":"AstraZeneca","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/17/2024","start_date":" 06/17/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-13"},{"id":"16b1dd6d-59d8-4e1c-af67-ef5bc5127aa0","acronym":"L2-268","url":"https://clinicaltrials.gov/study/NCT06762483","created_at":"2025-02-26T07:26:35.306Z","updated_at":"2025-02-26T07:26:35.306Z","phase":"","brief_title":"Integrated Testing Strategy for Simultaneous Detection of ESR-1 and GBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,","source_id_and_acronym":"NCT06762483 - L2-268","lead_sponsor":"European Institute of Oncology","biomarkers":" ER","pipe":" | ","alterations":" ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2024","start_date":" 12/20/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-07"},{"id":"21b440b3-9948-4e04-97d3-76344957756f","acronym":"PEARL","url":"https://clinicaltrials.gov/study/NCT02028507","created_at":"2021-01-17T17:20:18.722Z","updated_at":"2025-02-25T15:05:49.973Z","phase":"Phase 3","brief_title":"Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors","source_id_and_acronym":"NCT02028507 - PEARL","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • capecitabine • fulvestrant • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 693","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 01/14/2019","primary_completion_date":" 01/14/2019","study_txt":" Completion: 01/11/2021","study_completion_date":" 01/11/2021","last_update_posted":"2024-09-25"},{"id":"1250c179-6562-4901-865f-17545e9bd303","acronym":"ML43171","url":"https://clinicaltrials.gov/study/NCT05306340","created_at":"2022-04-01T21:53:28.059Z","updated_at":"2024-07-02T16:34:58.786Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","source_id_and_acronym":"NCT05306340 - ML43171","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • fulvestrant • dexamethasone • exemestane • giredestrant (RG6171)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-05"},{"id":"8637b136-3de4-40fa-8293-aa26c472595a","acronym":"SERENA-6","url":"https://clinicaltrials.gov/study/NCT04964934","created_at":"2021-07-16T13:53:17.689Z","updated_at":"2024-07-02T16:34:59.080Z","phase":"Phase 3","brief_title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","source_id_and_acronym":"NCT04964934 - SERENA-6","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-06-04"},{"id":"7d23d816-d6f4-41e9-9cb9-d2526c0cc2b3","acronym":"OPERA-01","url":"https://clinicaltrials.gov/study/NCT06016738","created_at":"2023-08-30T14:08:41.909Z","updated_at":"2024-07-02T16:34:59.724Z","phase":"Phase 3","brief_title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06016738 - OPERA-01","lead_sponsor":"Olema Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-31"},{"id":"348b6bee-e334-487c-b8b5-38e99c466308","acronym":"ADELA","url":"https://clinicaltrials.gov/study/NCT06382948","created_at":"2024-04-24T17:32:40.686Z","updated_at":"2024-07-02T16:35:07.380Z","phase":"Phase 3","brief_title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","source_id_and_acronym":"NCT06382948 - ADELA","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • ER mutation • ESR1 mutation • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-26"},{"id":"41c64d00-75dd-4fa2-9ce1-9e342496ddc1","acronym":"ELAINE 1","url":"https://clinicaltrials.gov/study/NCT03781063","created_at":"2021-01-18T18:42:03.161Z","updated_at":"2024-07-02T16:35:08.944Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT03781063 - ELAINE 1","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"},{"id":"fab65276-bb46-4e33-bd0f-2cadd6a74b15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04256941","created_at":"2021-01-18T20:41:27.231Z","updated_at":"2024-07-02T16:35:09.598Z","phase":"Phase 2","brief_title":"Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study","source_id_and_acronym":"NCT04256941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2024-04-16"},{"id":"a01b13a9-a81d-4566-9d3e-266d627428f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02738866","created_at":"2021-01-18T13:24:51.951Z","updated_at":"2024-07-02T16:35:21.102Z","phase":"Phase 2","brief_title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","source_id_and_acronym":"NCT02738866","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR • PI3K","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation","tags":["HER-2 • ER • PGR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-02"},{"id":"d65863ad-7efa-4719-a1a1-47fc18cfeebf","acronym":"iRetroBC","url":"https://clinicaltrials.gov/study/NCT06131424","created_at":"2023-11-14T22:15:41.310Z","updated_at":"2024-07-02T16:35:22.353Z","phase":"","brief_title":"NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06131424 - iRetroBC","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 2700","initiation":"Initiation: 03/04/2024","start_date":" 03/04/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-24"},{"id":"2f8a360e-0756-4c29-9da9-648e54e67f50","acronym":"H3B-6545-A001-101","url":"https://clinicaltrials.gov/study/NCT03250676","created_at":"2021-01-17T17:33:34.840Z","updated_at":"2024-07-02T16:35:25.240Z","phase":"Phase 1/2","brief_title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03250676 - H3B-6545-A001-101","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3B-6545"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 08/17/2017","start_date":" 08/17/2017","primary_txt":" Primary completion: 10/26/2023","primary_completion_date":" 10/26/2023","study_txt":" Completion: 10/26/2023","study_completion_date":" 10/26/2023","last_update_posted":"2023-12-25"},{"id":"5a4c99c4-88bf-4540-b466-6889c483ee21","acronym":"ESTHER","url":"https://clinicaltrials.gov/study/NCT05716516","created_at":"2023-02-08T18:00:21.333Z","updated_at":"2024-07-02T16:35:29.139Z","phase":"Phase 2","brief_title":"STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)","source_id_and_acronym":"NCT05716516 - ESTHER","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" ER","pipe":" | ","alterations":" ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/04/2023","start_date":" 05/04/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-11-15"},{"id":"fa0a1bac-6932-4a6b-9fe9-e4d705b6bba8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06064812","created_at":"2023-10-03T19:11:25.019Z","updated_at":"2024-07-02T16:35:33.307Z","phase":"Phase 1","brief_title":"A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.","source_id_and_acronym":"NCT06064812","lead_sponsor":"Forward Pharmaceuticals Co., Ltd.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-10-17"},{"id":"ebecf9c8-7521-4456-bb66-ff2f533a0378","acronym":"","url":"https://clinicaltrials.gov/study/NCT06062498","created_at":"2023-10-02T20:12:30.489Z","updated_at":"2024-07-02T16:35:35.109Z","phase":"Phase 2","brief_title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06062498","lead_sponsor":"Northwestern University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • Orserdu (elacestrant)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-02"},{"id":"3fa65445-060e-4ce9-9785-7480baa8f775","acronym":"PADA-1","url":"https://clinicaltrials.gov/study/NCT03079011","created_at":"2021-01-18T15:10:06.516Z","updated_at":"2024-07-02T16:35:36.038Z","phase":"Phase 3","brief_title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","source_id_and_acronym":"NCT03079011 - PADA-1","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ER mutation • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1017","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-22"},{"id":"6ed06cab-c7c7-450b-93d9-67848afd9e45","acronym":"CICLADES","url":"https://clinicaltrials.gov/study/NCT03318263","created_at":"2021-01-18T16:23:13.868Z","updated_at":"2024-07-02T16:35:40.862Z","phase":"","brief_title":"CIrCuLAting Dna ESr1 Gene Mutations Analysis","source_id_and_acronym":"NCT03318263 - CICLADES","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2 • ER • PIK3CA • AKT1","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PIK3CA • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-08-04"},{"id":"17e179ba-af45-4910-b3e7-1e15f44c5d04","acronym":"","url":"https://clinicaltrials.gov/study/NCT05927779","created_at":"2023-07-03T16:10:23.510Z","updated_at":"2024-07-02T16:35:44.245Z","phase":"Phase 1/2","brief_title":"Study of TFX06 in Women With Advanced Breast Cancer.","source_id_and_acronym":"NCT05927779","lead_sponsor":"Shenzhen Yangli Pharmaceutical Technology Co., Ltd","biomarkers":" HER-2 • CDK4","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["HER-2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFX06"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 04/17/2023","start_date":" 04/17/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-30"},{"id":"4a21145c-913f-4666-866a-6508e1e7591f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04174352","created_at":"2021-01-18T20:21:47.085Z","updated_at":"2024-07-02T16:35:45.655Z","phase":"Phase 1","brief_title":"FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer","source_id_and_acronym":"NCT04174352","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • CDK4","pipe":" | ","alterations":" HER-2 negative • ER mutation • ESR1 mutation • ER expression","tags":["HER-2 • ER • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ESR1 mutation • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-06-15"},{"id":"72388a7b-c5fa-4e38-9b49-b137f2d7eff5","acronym":"MAGNETIC1","url":"https://clinicaltrials.gov/study/NCT05814224","created_at":"2023-04-14T14:03:25.361Z","updated_at":"2024-07-02T16:35:50.565Z","phase":"","brief_title":"Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA","source_id_and_acronym":"NCT05814224 - MAGNETIC1","lead_sponsor":"Centro di Riferimento Oncologico - Aviano","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ESR1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 164","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-14"},{"id":"7abaedd7-8fbf-40ad-bbb9-d9b1ef0caeb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02913430","created_at":"2021-01-18T14:18:14.838Z","updated_at":"2024-07-02T16:36:27.482Z","phase":"Phase 1","brief_title":"Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib","source_id_and_acronym":"NCT02913430","lead_sponsor":"Shannon Puhalla","biomarkers":" ER","pipe":" | ","alterations":" ER mutation • ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER mutation • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 10/28/2021","study_completion_date":" 10/28/2021","last_update_posted":"2021-07-26"},{"id":"93381f81-4b25-4c4c-a9b9-26e5ccaad10e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03161834","created_at":"2021-01-18T15:35:25.348Z","updated_at":"2024-07-02T16:36:29.956Z","phase":"","brief_title":"Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer","source_id_and_acronym":"NCT03161834","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ESR1 mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/13/2017","start_date":" 01/13/2017","primary_txt":" Primary completion: 07/09/2020","primary_completion_date":" 07/09/2020","study_txt":" Completion: 07/09/2020","study_completion_date":" 07/09/2020","last_update_posted":"2021-05-21"},{"id":"2ddde9b9-3e08-486f-9a28-c0cd60c06cbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04212702","created_at":"2021-01-18T20:30:47.911Z","updated_at":"2025-02-25T15:43:49.162Z","phase":"","brief_title":"ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments","source_id_and_acronym":"NCT04212702","lead_sponsor":"National Taiwan University Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ESR1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ESR1 mutation • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2021-01-12"}]